EraCal Therapeutics

Executive Summary

EraCal Therapeutics is a Swiss biotechnology company leveraging a unique zebrafish-based phenotypic drug discovery platform to identify novel small molecule therapeutics for metabolic disorders, primarily obesity. Founded in 2018 as a spin-off from the University of Zurich and Harvard University, the company is currently in the pre-clinical stage, focusing on first-in-class treatments that regulate appetite and metabolism. By using zebrafish to screen for targets and compounds, EraCal aims to uncover new biology and develop oral small molecule drugs with a potentially differentiated mechanism of action. The company is privately held and headquartered in Zurich, Switzerland. While specific financial details and pipeline status remain undisclosed, EraCal's approach addresses a significant unmet need in the global obesity epidemic, which is increasingly treated with pharmacotherapy. The platform's ability to identify novel targets may reduce competition and offer a unique value proposition in the metabolic disease space.

Upcoming Catalysts (preview)

• Q4 2026Initiation of lead optimization for obesity candidate40% success
• Q1 2027Publication of preclinical proof-of-concept data in a peer-reviewed journal60% success
• Q3 2026Series A financing round to advance pipeline70% success